Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Sumin Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: HY-KIST Bioconvergence, Hanyang University, Seoul, South Korea. Hauptthemen laut MEDLINE: PR-SET Domains, Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Research Council of Science and Technology, National Research Foundation of Korea.
Abstract (Originalsprache)
NSD3/WHSC1L1 lysine methyltransferase promotes the transcription of target genes through di‐ or tri‐methylation at histone H3K36 using SAM as a cofactor. Genetic alterations such as amplification and gain‐of‐function mutation of NSD3 act as oncogenic drivers in several cancers including squamous cell lung cancer and breast cancer. NSD3 is an important therapeutic target for cancers, but the reported NSD3 inhibitors targeting the catalytic SET domain are very rare and show a poor activity. Herein, from a virtual library screening and the subsequent medicinal chemistry optimization, we identified a novel class of NSD3 inhibitors. Our docking analysis and pulldown result suggested that the most potent analogue 13i shows a unique, bivalent binding mode interacting with both SAM‐binding site and BT3‐bindig site within the SET domain. We found 13i inhibits NSD3 activity with IC 50 = 287 μM in vitro and suppresses the proliferation of JIMT1 breast cancer cells with GI 50 = 36.5 μM, which express a high level of NSD3. Also, 13i downregulated the levels of H3K36me2/3 in a dose‐dependent manner. Our study could provide an insight in designing high‐affinity NSD3 inhibitors. Also, as the acrylamide group of 13i was predicted to position near Cys1265 in the BT3‐binding site, further optimization would lead to a discovery of novel irreversible NSD3 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HY-KIST Bioconvergence, Hanyang University, Seoul, South Korea.
- Medicinal Materials Research Center, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
- Computational Science Research Center, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
- Advanced Analysis Data Center, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
- Department of Pathology, Hanyang University College of Medicine, Seoul, South Korea.
ORCID-Profile: Wooyoung Hur
Förderung
- National Research Council of Science and Technology
- National Research Foundation of Korea
Zitieren
APA
Kim, S., Hwang, I., Kim, S. H., Chung, H. W., Ji, M. J., Moon, S., Park, H. M., Kong, G., & Hur, W. (2023). Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14249
Vancouver
Kim S, Hwang I, Kim SH, Chung HW, Ji MJ, Moon S, et al. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14249
BibTeX
@article{Kim2023,
author = {Kim, Sumin and Hwang, Injeoung and Kim, Suhn Hyung and Chung, Hwan Won and Ji, Mi-Jung and Moon, Sojeong and Park, Hyun-Mee and Kong, Gu and Hur, Wooyoung},
title = {Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14249}
}
EUVIMED